Xin Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xin Liang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Xudong Zhang
Department of Pharmacology, Molecular Cancer Research Center, Zhongshan School of Medicine, Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, Guangdong, 518107, PR China
3 shared publications Fanqiang Meng
Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases School of Medicine Shenzhen Campus of Sun Yat‐Sen University Sun Yat‐Sen University Shenzhen Guangdong 518107 P. R. China
2 shared publicationsXiaozhou Zhang
Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases School of Medicine Shenzhen Campus of Sun Yat‐Sen University Sun Yat‐Sen University Shenzhen Guangdong 518107 P. R. China
2 shared publicationsYumeng Ma
Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases School of Medicine Shenzhen Campus of Sun Yat‐Sen University Sun Yat‐Sen University Shenzhen Guangdong 518107 P. R. China
2 shared publicationsZhongda Lin
Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases School of Medicine Shenzhen Campus of Sun Yat‐Sen University Sun Yat‐Sen University Shenzhen Guangdong 518107 P. R. China
2 shared publicationsChanjuan Li
Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases School of Medicine Shenzhen Campus of Sun Yat‐Sen University Sun Yat‐Sen University Shenzhen Guangdong 518107 P. R. China
1 shared publication
Latest Publications
- Open Access
- 28 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (16) , e2501139
Bioengineering Platelets Presenting PD‐L1, Galectin‐9 and BTLA to Ameliorate Type 1 Diabetes
Autoimmune destruction of pancreatic β‐cells leads to impaired insulin production and onset of type 1 diabetes (T1D). Hence, immunomodulation of pancreas‐infiltrated immune cells especially the β‐cells autoreactive‐T cells is a promising way to hinder and reverse the progress of T1D. Herein, megakaryocytes are primed with interferon‐γ (IFN‐γ) to produce platelets presenting high levels of immunosuppressive checkpoint ligands including programmed death‐ligand 1 (PD‐L1), Programmed Death‐Ligand 2 (PD‐L2), the B and T lymphocyte attenuator (BTLA) and Galectin‐9 (Gal‐9), termed as IFN‐γ platelets. The IFN‐γ platelets bound and interacted with T cells through immune checkpoint ligands and receptors, which efficaciously induced T cell exhaustion and apoptosis in vitro. Virtually, NOD diabetes mice received IFN‐γ platelets treatments prominently preserved β‐cell integrity and insulin production, ultimately hindering the progress to hyperglycemia. Intriguingly, both the amount and activity of the pancreas infiltrate‐T cells intensively reduced, whereas the magnitude of regulatory T cells (Tregs) remarkably increased, which is attributed to IFN‐γ platelets treatments. Moreover, IFN‐γ platelets treatment instigated macrophage polarization toward an anti‐inflammatory M2 phenotype that may stimulate pancreatic angiogenesis, and promote β‐cell proliferation, consequently ameliorating the new‐onset T1D.
- 28 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (16) , e2501139
Open AccessBioengineering Platelets Presenting PD‐L1, Galectin‐9 and BTLA to Ameliorate Type 1 Diabetes
Autoimmune destruction of pancreatic β‐cells leads to impaired insulin production and onset of type 1 diabetes (T1D). Hence, immunomodulation of pancreas‐infiltrated immune cells especially the β‐cells autoreactive‐T cells is a promising way to hinder and reverse the progress of T1D. Herein, megakaryocytes are primed with interferon‐γ (IFN‐γ) to produce platelets presenting high levels of immunosuppressive checkpoint ligands including programmed death‐ligand 1 (PD‐L1), Programmed Death‐Ligand 2 (PD‐L2), the B and T lymphocyte attenuator (BTLA) and Galectin‐9 (Gal‐9), termed as IFN‐γ platelets. The IFN‐γ platelets bound and interacted with T cells through immune checkpoint ligands and receptors, which efficaciously induced T cell exhaustion and apoptosis in vitro. Virtually, NOD diabetes mice received IFN‐γ platelets treatments prominently preserved β‐cell integrity and insulin production, ultimately hindering the progress to hyperglycemia. Intriguingly, both the amount and activity of the pancreas infiltrate‐T cells intensively reduced, whereas the magnitude of regulatory T cells (Tregs) remarkably increased, which is attributed to IFN‐γ platelets treatments. Moreover, IFN‐γ platelets treatment instigated macrophage polarization toward an anti‐inflammatory M2 phenotype that may stimulate pancreatic angiogenesis, and promote β‐cell proliferation, consequently ameliorating the new‐onset T1D.
- Open Access
- 5 December 2022
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 11 (12) , e12289
Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
Neoantigens derived from mutant proteins in tumour cells could elicit potent personalized anti‐tumour immunity. Nevertheless, the layout of vaccine vehicle and synthesis of neoantigen are pivotal for stimulating robust response. The power of synthetic biology enables genetic programming bacteria to produce therapeutic agents under contol of the gene circuits. Herein, we genetically engineered bacteria to synthesize fusion neoantigens, and prepared bacteria derived vesicles (BDVs) presenting the neoantigens (BDVs‐Neo) as personalized therapeutic vaccine to drive systemic antitumour response. BDVs‐Neo and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) were inoculated subcutaneously within hydrogel (Gel), whereas sustaining release of BDVs‐Lipopolysaccharide (LPS) and GM‐CSF recruited the dendritic cells (DCs). Virtually, Gel‐BDVs‐Neo combined with the programmed cell death protein 1 (PD‐1) antibody intensively enhanced proliferation and activation of tumour‐infiltrated T cells, as well as memory T cell clone expansion. Consequently, BDVs‐Neo combining with checkpoint blockade therapy effectively prevented tumour relapse and metastasis.
- 5 December 2022
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 11 (12) , e12289
Open AccessBiosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
Neoantigens derived from mutant proteins in tumour cells could elicit potent personalized anti‐tumour immunity. Nevertheless, the layout of vaccine vehicle and synthesis of neoantigen are pivotal for stimulating robust response. The power of synthetic biology enables genetic programming bacteria to produce therapeutic agents under contol of the gene circuits. Herein, we genetically engineered bacteria to synthesize fusion neoantigens, and prepared bacteria derived vesicles (BDVs) presenting the neoantigens (BDVs‐Neo) as personalized therapeutic vaccine to drive systemic antitumour response. BDVs‐Neo and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) were inoculated subcutaneously within hydrogel (Gel), whereas sustaining release of BDVs‐Lipopolysaccharide (LPS) and GM‐CSF recruited the dendritic cells (DCs). Virtually, Gel‐BDVs‐Neo combined with the programmed cell death protein 1 (PD‐1) antibody intensively enhanced proliferation and activation of tumour‐infiltrated T cells, as well as memory T cell clone expansion. Consequently, BDVs‐Neo combining with checkpoint blockade therapy effectively prevented tumour relapse and metastasis.
- Open Access
- 2 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 997287
Leverage biomaterials to modulate immunity for type 1 diabetes
The pathogeny of type 1 diabetes (T1D) is mainly provoked by the β-cell loss due to the autoimmune attack. Critically, autoreactive T cells firsthand attack β-cell in islet, that results in the deficiency of insulin in bloodstream and ultimately leads to hyperglycemia. Hence, modulating immunity to conserve residual β-cell is a desirable way to treat new-onset T1D. However, systemic immunosuppression makes patients at risk of organ damage, infection, even cancers. Biomaterials can be leveraged to achieve targeted immunomodulation, which can reduce the toxic side effects of immunosuppressants. In this review, we discuss the recent advances in harness of biomaterials to immunomodulate immunity for T1D. We investigate nanotechnology in targeting delivery of immunosuppressant, biological macromolecule for β-cell specific autoreactive T cell regulation. We also explore the biomaterials for developing vaccines and facilitate immunosuppressive cells to restore immune tolerance in pancreas.
- 2 November 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 997287
Open AccessLeverage biomaterials to modulate immunity for type 1 diabetes
The pathogeny of type 1 diabetes (T1D) is mainly provoked by the β-cell loss due to the autoimmune attack. Critically, autoreactive T cells firsthand attack β-cell in islet, that results in the deficiency of insulin in bloodstream and ultimately leads to hyperglycemia. Hence, modulating immunity to conserve residual β-cell is a desirable way to treat new-onset T1D. However, systemic immunosuppression makes patients at risk of organ damage, infection, even cancers. Biomaterials can be leveraged to achieve targeted immunomodulation, which can reduce the toxic side effects of immunosuppressants. In this review, we discuss the recent advances in harness of biomaterials to immunomodulate immunity for T1D. We investigate nanotechnology in targeting delivery of immunosuppressant, biological macromolecule for β-cell specific autoreactive T cell regulation. We also explore the biomaterials for developing vaccines and facilitate immunosuppressive cells to restore immune tolerance in pancreas.